



DIAGNOS

Your Knowledge Partner

PRESS RELEASE

OTCQB: DGNOF
TSXV: ADK
SOURCE: DIAGNOS Inc.

2017.12.06

DIAGNOS Receives Support from Export Development Canada (EDC) for the Issuance of a Performance Bond for the ISSSTE Contract

Brossard, Quebec, Canada – December 06, 2017 - DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its *FLAIRE* platform based on Artificial Intelligence (AI), announces today that EDC has agreed to act as guarantor in connection with issuance of a performance bond under the terms of the agreement with ISSSTE, initially announced on July 17th of this year.

“We are pleased with EDC’s assistance which enables us to comply with a contract requirement to provide a CAD \$500,000 performance bond for the delivery of our CARA services to ISSSTE. Performance bonds are commonly required when rendering services to governmental agencies. Last year, we had to provide cash warranty in the amount of USD \$180,000 to secure the issuance of the performance bond as part of our first contract with ISSSTE. After a successful program last year, EDC approved guaranteeing this year’s CAD \$500,000 performance bond without any cash warranty from DIAGNOS,” said André Larente, President of DIAGNOS.

About Export Development Canada (EDC)

EDC is Canada’s export credit agency. EDC is engaged in supporting and developing Canada’s export trade by helping Canadian companies respond to international business opportunities. EDC is a self-financing, Crown corporation that operates at arm’s length from the Government of Canada.

Additional information on EDC is available at www.edc.ca.

About DIAGNOS and its technologies

DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging, text and traditional data mining. DIAGNOS has developed its own Artificial Intelligence (“AI”) technologies, CARA and *FLAIRE*. *FLAIRE* is a powerful AI engine that provides the capability of analyzing large and complex data sets. Using Deep Learning methodology combined with our own proprietary algorithms we can deploy rapidly new solutions to the healthcare market

Additional information on DIAGNOS is available at www.diagnos.ca and www.sedar.com.

For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca



DIAGNOS

Your Knowledge Partner

PRESS RELEASE

OTCQB: DGNOF
TSXV : ADK
SOURCE : DIAGNOS Inc.

Daniel Renaud or Thomas Renaud, Managing Directors
Arrowhead Business and Investment Decisions, LLC
Tel: +1 212 619 6889, ext. 7010
diagnos@arrowheadbid.com

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.